Autopsy report · NCT03972709

A Study Assessing the Safety, Tolerability, and Efficacy of Galegenimab (FHTR2163) in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration (AMD)

Cause of deathFutility Automatic label, confidence 0.9, unverified. How labels are made.

“The benefit to risk balance did not support further treatment with galegenimab (FHTR2163).”

The sponsor’s own words in the registry.

Life of this trial

Ran for about 3 years 5 months before it stopped.
372 participants enrolled.
Results were posted on the registry 1 year 5 months after it ended.

Vital statistics

Status: Terminated
Phase: Phase 2
Sponsor: Genentech, Inc.
Sponsor type: Industry
Conditions: Macular Degeneration, Age-Related; Geographic Atrophy
Interventions: Galegenimab; Sham Control
Participants: 372
Sites: 72
Countries: United States

Look deeper

The official registry record (the source of truth)
Record history: every change the sponsor made
Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.